Search
Now showing items 171-180 of 224
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
(WILEY, 2023-05-01)
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], ...
Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients.
(ELSEVIER SCI LTD, 2020-12-01)
PURPOSE: No studies extensively compared the young adults (YA, 18-39 years), middle-aged (40-69 years), and elderly (≥70 years) population with primary high-grade extremity soft tissue sarcoma (eSTS). This study aimed to ...
Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives.
(BMC, 2023-05-31)
BACKGROUND: Breast cancer is the most frequent cancer in women and remains the second leading cause of death in Western countries. It represents a heterogeneous group of diseases with diverse tumoral behaviour, treatment ...
A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules.
(ELSEVIER, 2022-12-01)
BACKGROUND: Large lung nodules (≥15 mm) have the highest risk of malignancy, and may exhibit important differences in phenotypic or clinical characteristics to their smaller counterparts. Existing risk models do not stratify ...
Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
(WILEY, 2023-06-07)
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the ...
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
(ELSEVIER, 2022-09-13)
Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes ...
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-11-10)
PURPOSE: Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor-resistant metastatic ...
DNA methylation age in paired tumor and adjacent normal breast tissue in Chinese women with breast cancer.
(BMC, 2023-03-30)
BACKGROUND: Few studies have examined epigenetic age acceleration (AA), the difference between DNA methylation (DNAm) predicted age and chronological age, in relation to somatic genomic features in paired cancer and normal ...
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
(ELSEVIER SCI LTD, 2022-03-01)
OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) ...
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
(SPRINGER, 2020-11-26)
INTRODUCTION: Management of locally advanced, unresectable, or metastatic (adv/met) esophageal adenocarcinoma (EAC) follows clinical guidance for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, ...